Jim Cramer Says “Buy the Stock of CVS, I Sure Wish I’d Done It for My Trust”
Yahoo Finance ·
Jim Cramer Says “Buy the Stock of CVS, I Sure Wish I’d Done It for My Trust” Syeda Seirut Javed Mon, July 13, 2026 at 11:25 AM EDT 1 min read CVS CVS Health Corporation (NYSE: CVS ) was among Jim Cramer's stock calls on Mad Money, as he advised investors to stick with the largest tech companies in the market . Noting that healthcare stocks have been out of favor for some time, a caller asked if the stock is a buy, sell, or hold. Cramer stated: It's a strong buy. Why? Because this David Joyner has come through the scrum. Well, where do we see a Walgreens? Very few of them. We don't see Rite Aids anymore. They're gone. The only real competitor to CVS is Amazon, and CVS has got Aetna; Amazon doesn't. Aetna is crushing it. Buy the stock of CVS. I sure wish I'd done it for my Trust. Stock market data. Photo by Alesia Kozik on Pexels CVS Health Corporation (NYSE:CVS) provides healthcare solutions through insurance, pharmacy benefit management, and retail pharmacy services. Cramer discussed the stock during the July 1 episode, as he commented: How about these outsized moves in the health insurers and the drug distributors? Oh, I like these. I bet the gains in CVS will be long-lasting. I like UnitedHealth very much here. Humana is doing great. While we acknowledge the potential of CVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock . READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years Disclosure: None. Follow Insider Monkey on Google News .
AI 시장 분석
Jim Cramer recommended a strong buy on CVS Health, citing its strengthened market dominance following the decline of rivals Walgreens and Rite Aid. He particularly highlighted the strong performance of its insurance segment through Aetna as a key factor in gaining a competitive edge over Amazon. Investors should note the valuation appeal of the healthcare sector and CVS's monopolistic market position.
상승 영향
- Biotech — Strengthened monopoly status due to the exit of competitors and robust performance of Aetna are primary growth drivers. The sector-wide undervaluation highlights its potential for long-term earnings generation.
DYAX 전담 분석
CVS Health is leveraging its integrated business model to solidify its market footprint. With major competitors struggling, the company has effectively captured a larger market share. The synergy between its pharmacy retail operations and Aetna's insurance business creates a formidable moat that differentiates it from pure-play digital competitors like Amazon. The current valuation provides an attractive entry point for long-term investors looking for stability in the healthcare space.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 54% · Bearish (Short) 46%
276 participants